This company has been marked as potentially delisted and may not be actively trading. Bioblast Pharma (ORPN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock ORPN vs. GRTX, ADXS, BPTH, ASLN, OGEN, ATXI, EVFM, PBLA, PTPI, and TRVNShould you be buying Bioblast Pharma stock or one of its competitors? The main competitors of Bioblast Pharma include Galera Therapeutics (GRTX), Ayala Pharmaceuticals (ADXS), Bio-Path (BPTH), ASLAN Pharmaceuticals (ASLN), Oragenics (OGEN), Avenue Therapeutics (ATXI), Evofem Biosciences (EVFM), Panbela Therapeutics (PBLA), Petros Pharmaceuticals (PTPI), and Trevena (TRVN). These companies are all part of the "medical" sector. Bioblast Pharma vs. Its Competitors Galera Therapeutics Ayala Pharmaceuticals Bio-Path ASLAN Pharmaceuticals Oragenics Avenue Therapeutics Evofem Biosciences Panbela Therapeutics Petros Pharmaceuticals Trevena Galera Therapeutics (NASDAQ:GRTX) and Bioblast Pharma (NASDAQ:ORPN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings. Does the media prefer GRTX or ORPN? In the previous week, Galera Therapeutics' average media sentiment score of 0.00 equaled Bioblast Pharma'saverage media sentiment score. Company Overall Sentiment Galera Therapeutics Neutral Bioblast Pharma Neutral Is GRTX or ORPN more profitable? Company Net Margins Return on Equity Return on Assets Galera TherapeuticsN/A N/A -99.34% Bioblast Pharma N/A N/A N/A Which has more risk and volatility, GRTX or ORPN? Galera Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500. Comparatively, Bioblast Pharma has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Which has stronger valuation & earnings, GRTX or ORPN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalera TherapeuticsN/AN/A-$59.08M-$0.26-0.10Bioblast PharmaN/AN/A-$5.94MN/AN/A Do institutionals & insiders believe in GRTX or ORPN? 50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 4.5% of Bioblast Pharma shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryGalera Therapeutics beats Bioblast Pharma on 3 of the 5 factors compared between the two stocks. Get Bioblast Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORPN vs. The Competition Export to ExcelMetricBioblast PharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$471K$785.88M$5.69B$9.50BDividend YieldN/A4.84%4.58%4.01%P/E RatioN/A1.4428.2320.08Price / SalesN/A25.35430.5089.23Price / CashN/A19.5636.2258.56Price / Book0.156.928.665.88Net Income-$5.94M-$4.17M$3.25B$258.72M Bioblast Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORPNBioblast PharmaN/A$1.12-1.8%N/A-19.6%$471KN/A0.00N/AGap UpHigh Trading VolumeGRTXGalera TherapeuticsN/A$0.03-11.0%N/A-80.0%$2.01MN/A-0.0830ADXSAyala PharmaceuticalsN/A$0.03flatN/A-75.2%$1.42M$3.24M0.0020BPTHBio-Path0.8082 of 5 stars$0.16+0.6%N/A-91.7%$1.31MN/A0.0010ASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330OGENOragenics0.0595 of 5 stars$1.43+0.7%N/A-95.4%$1.18MN/A-0.205ATXIAvenue Therapeutics2.3069 of 5 stars$0.36-0.4%N/A-86.2%$1.14MN/A0.024Gap DownEVFMEvofem Biosciences1.3295 of 5 stars$0.01-5.1%N/A-18.5%$1.10M$11.39M-0.01120Gap DownPBLAPanbela Therapeutics0.2989 of 5 stars$0.19-21.0%N/A-53.1%$903KN/A0.006PTPIPetros PharmaceuticalsN/A$0.03+1.1%N/A-99.7%$897K$5.11M-0.0120TRVNTrevena1.1673 of 5 stars$0.91-2.3%$5.00+449.5%-84.0%$873K$443K-0.0240 Related Companies and Tools Related Companies Galera Therapeutics Competitors Ayala Pharmaceuticals Competitors Bio-Path Competitors ASLAN Pharmaceuticals Competitors Oragenics Competitors Avenue Therapeutics Competitors Evofem Biosciences Competitors Panbela Therapeutics Competitors Petros Pharmaceuticals Competitors Trevena Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORPN) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioblast Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioblast Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
